Base de dados : MEDLINE
Pesquisa : D12.776.124.486.485.114.254.150 [Categoria DeCS]
Referências encontradas : 350 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 35 ir para página                         

  1 / 350 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28829831
[Au] Autor:Hohn O; Norley S; Kücherer C; Bazarbachi A; El Hajj H; Marcus U; Zimmermann R; Bannert N
[Ad] Endereço:Department of Infectious Diseases, Division for HIV and Other Retroviruses, Robert Koch Institute, Berlin, Germany.
[Ti] Título:No significant HTLV seroprevalence in German people who inject drugs.
[So] Source:PLoS One;12(8):e0183496, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although human T-lymphotropic virus (HTLV) is transmitted via the same routes as human immunodeficiency virus (HIV), its worldwide seroprevalence differs drastically because HTLV is transmitted mainly via infected cells rather than free virus. The sharing of needles and other equipment places people who inject drugs (PWID) at particularly high-risk for such blood-borne diseases. METHODS: To validate the methodology used to process and analyze the dried blood spots (DBS) utilized in the study, dried serum spots (DSS) with dilutions of sera from known HTLV infected individuals were analyzed by ELISA and Western blot. DBS collected between 2011 and 2015 from 2,077 PWID in eight German cities recruited by respondent-driven sampling were tested for HTLV-specific antibodies. RESULTS: The validation demonstrated that the use of DSS allowed identification of samples with even low titers of HTLV-specific antibodies, although a confirmatory Western blot with an additional venous blood sample would often be required. Despite numerous HIV and HCV positive individuals being identified within the study population, none tested positive for HTLV. CONCLUSION: While the HIV and HCV prevalences in German PWID are comparable to those in other European countries, the very low prevalence of HTLV reflects the situation in the general population.
[Mh] Termos MeSH primário: Infecções por Deltaretrovirus/sangue
Abuso de Substâncias por Via Intravenosa/complicações
[Mh] Termos MeSH secundário: Anticorpos Antideltaretrovirus/sangue
Infecções por Deltaretrovirus/complicações
Ensaio de Imunoadsorção Enzimática
Alemanha/epidemiologia
Seres Humanos
Estudos Soroepidemiológicos
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170823
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183496


  2 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28212879
[Au] Autor:Coelho-Dos-Reis JG; Peruhype-Magalhães V; Pascoal-Xavier MA; de Souza Gomes M; do Amaral LR; Cardoso LM; Jonathan-Gonçalves J; Ribeiro ÁL; Starling AL; Ribas JG; Gonçalves DU; de Freitas Carneiro-Proietti AB; Teixeira-Carvalho A; Martins-Filho OA; GIPH
[Ad] Endereço:Grupo Integrado de Pesquisas em Biomarcadores - Centro de Pesquisas René Rachou - FIOCRUZ-Minas, Belo Horizonte, MG, Brazil. Electronic address: jordana.reis@cpqrr.fiocruz.br.
[Ti] Título:Flow cytometric-based protocols for assessing anti-MT-2 IgG1 reactivity: High-dimensional data handling to define predictors for clinical follow-up of Human T-cell Leukemia virus type-1 infection.
[So] Source:J Immunol Methods;444:36-46, 2017 May.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The present work provides an innovative methodological approach to assess the anti-HTLV-1 IgG1 reactivity with practical application in clinical laboratory. Serum from non-infected healthy controls (NI) and HTLV-1-infected patients, categorized as asymptomatic (AS), putatively progressing to HTLV-1 associated myelopathy/tropical spastic paraparesis - HAM/TSP (pHAM) or with clinical diagnosis of HAM/TSP (HT) were assayed in two-parallel flow cytometry platforms, referred as: Fix and Fix&Perm protocols. Operating-characteristics analysis indicated that a single pair of attributes ("serum dilution/cut-off") for Fix and Fix&Perm protocols presented excellent performance for the diagnosis of HTLV-1 infection. Conversely, Fix and Fix&Perm protocols displayed weak/moderate overall performances when applied with prognosis purposes of HTLV-1 infection. A panoramic snapshot provided by the reactivity boards revealed clearly the higher sensitivity of Fix&Perm protocol for detecting seropositivity for HT, suggesting that stepwise combinatory criteria would improve the global performance of using a single pair of attributes. Three data mining strategies were tested, including endpoint titer analysis, heatmap assemblage and decision tree analysis. Bi-dimensional heatmap analysis demonstrated that, while the clustering profile of NI vs HTLV-1 revealed segregation in opposite poles, AS vs HT presented discrete segregation but still displaying an intertwined distribution pattern. The combination of methods for segregating AS from HT displayed a moderate but superior global accuracy (85.7%; LOOCV=71.4%). The comprehensive data analysis support that the combination of methods have improved the performance to the differential diagnosis of AS and HT, with direct association with laboratorial records, including serum cytokine levels and proviral load.
[Mh] Termos MeSH primário: Anticorpos Antideltaretrovirus/sangue
Citometria de Fluxo
Técnica Indireta de Fluorescência para Anticorpo
Infecções por HTLV-I/diagnóstico
Ensaios de Triagem em Larga Escala/métodos
Vírus 1 Linfotrópico T Humano/imunologia
Imunoglobulina G/sangue
[Mh] Termos MeSH secundário: Algoritmos
Doenças Assintomáticas
Biomarcadores/sangue
Estudos de Casos e Controles
Linhagem Celular
Análise por Conglomerados
Citocinas/sangue
Mineração de Dados/métodos
Árvores de Decisões
Diagnóstico Diferencial
Progressão da Doença
Infecções por HTLV-I/sangue
Infecções por HTLV-I/imunologia
Infecções por HTLV-I/virologia
Seres Humanos
Paraparesia Espástica Tropical/sangue
Paraparesia Espástica Tropical/diagnóstico
Paraparesia Espástica Tropical/imunologia
Paraparesia Espástica Tropical/virologia
Valor Preditivo dos Testes
Reprodutibilidade dos Testes
Fatores de Tempo
Carga Viral
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Cytokines); 0 (Deltaretrovirus Antibodies); 0 (Immunoglobulin G)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170713
[Lr] Data última revisão:
170713
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170219
[St] Status:MEDLINE


  3 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:25780883
[Au] Autor:Heydari Zarnagh H; Ravanshad M; Pourfatollah AA; Rasaee MJ
[Ad] Endereço:Department of Clinical Biochemistry, Faculity of Medical Science, Tarbiat Modares University, Tehran, Iran Hafez.heydari@modares.ac.ir.
[Ti] Título:Expression and Purification of a Novel Computationally Designed Antigen for Simultaneously Detection of HTLV-1 and HBV Antibodies.
[So] Source:Iran J Allergy Asthma Immunol;14(2):168-78, 2015 Apr.
[Is] ISSN:1735-1502
[Cp] País de publicação:Iran
[La] Idioma:eng
[Ab] Resumo:Computational tools are reliable alternatives to laborious work in chimeric protein design. In this study, a chimeric antigen was designed using computational techniques for simultaneous detection of anti-HTLV-I and anti-HBV in infected sera. Databases were searched for amino acid sequences of HBV/HLV-I diagnostic antigens. The immunodominant fragments were selected based on propensity scales. The diagnostic antigen was designed using these fragments. Secondary and tertiary structures were predicted and the B-cell epitopes were mapped on the surface of built model. The synthetic DNA coding antigen was sub-cloned into pGS21a expression vector. SDS-PAGE analysis showed that glutathione fused antigen was highly expressed in E. coli BL21 (DE3) cells. The recombinant antigen was purified by nickel affinity chromatography. ELISA results showed that soluble antigen could specifically react with the HTLV-I and HBV infected sera. This specific antigen could be used as suitable agent for antibody-antigen based screening tests and can help clinicians in order to perform quick and precise screening of the HBV and HTLV-I infections.
[Mh] Termos MeSH primário: Biologia Computacional/métodos
Anticorpos Antideltaretrovirus/análise
Antígenos de Deltaretrovirus/imunologia
Anticorpos Anti-Hepatite B/análise
Antígenos de Superfície da Hepatite B/imunologia
Proteínas Recombinantes de Fusão/síntese química
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Antígenos de Deltaretrovirus/química
Antígenos de Deltaretrovirus/isolamento & purificação
Infecções por Deltaretrovirus/diagnóstico
Ensaio de Imunoadsorção Enzimática
Epitopos de Linfócito B/química
Epitopos de Linfócito B/imunologia
Hepatite B/diagnóstico
Antígenos de Superfície da Hepatite B/química
Seres Humanos
Epitopos Imunodominantes/química
Epitopos Imunodominantes/imunologia
Infecções Tumorais por Vírus/diagnóstico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies); 0 (Deltaretrovirus Antigens); 0 (Epitopes, B-Lymphocyte); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Surface Antigens); 0 (Immunodominant Epitopes); 0 (Recombinant Fusion Proteins)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:150318
[Lr] Data última revisão:
150318
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150318
[St] Status:MEDLINE


  4 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25267203
[Au] Autor:Laperche S; Pillonel J
[Ad] Endereço:Département d'études des agents transmissibles par le sang, Centre national de référence pour les hépatites B et C et du VIH en transfusion, Institut national de la transfusion sanguine, 6, rue Alexandre-Cabanel, 75015 Paris, France. Electronic address: slaperche@ints.fr.
[Ti] Título:[Relevance of safety measures to avoid HTLV transmission by transfusion in 2014].
[Ti] Título:Pertinence des mesures sécuritaires transfusionnelles vis-à-vis du HTLV en 2014..
[So] Source:Transfus Clin Biol;21(4-5):167-72, 2014 Nov.
[Is] ISSN:1953-8022
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:In high-income countries, the safety of blood transfusion related to viruses has reached a very high level, especially thanks to the implementation of multiple measures aimed at reducing the transfusion risk. The cost-effectiveness of these preventive measures is frequently discussed due to global financial resources, which are more and more limited. Hence, the revision of safety strategies is a key issue, especially when these strategies are redundant, as those implemented to avoid Human T-cell Lymphotropic Virus (HTLV) transmission, which are based on both antibodies screening and leucoreduction of blood products. The residual risk of the transmission of HTLV by transfusion has been recently estimated at 1 in 20 million donations (2010-2012) in France (excluding overseas territories). This estimation did not take into account the leucoreduction, which appears to be a very efficient preventive measure as the virus is strictly intra-cellular. To help decision-making, we have evaluated some parameters related to HTLV blood transmission. Firstly, the probability that an incident occurring during the leucoreduction process affects a HTLV-positive blood donation has been estimated at 1 in 178 million. Estimation of clinical consequences of HTLV-positive transfusions would affect 1 to 2 transfused-patients without leucoreduction, and one recipient every 192 years in case of 10% failures of the filtration method. Obviously, despite a risk, which appears to be controlled, HTLV screening will be disputed as soon as the efficiency of leucoreduction to totally prevent virus blood transmission will be proven and when pathogen inactivation methods are generalized to all blood cellular products.
[Mh] Termos MeSH primário: Segurança do Sangue/métodos
Infecções por Deltaretrovirus/prevenção & controle
Seleção do Doador
Reação Transfusional
[Mh] Termos MeSH secundário: Doadores de Sangue
Segurança do Sangue/normas
Análise Custo-Benefício
Tomada de Decisões
Anticorpos Antideltaretrovirus/sangue
Infecções por Deltaretrovirus/sangue
Infecções por Deltaretrovirus/diagnóstico
Infecções por Deltaretrovirus/epidemiologia
Infecções por Deltaretrovirus/transmissão
Seleção do Doador/economia
Seleção do Doador/métodos
França/epidemiologia
Seres Humanos
Procedimentos de Redução de Leucócitos/economia
Procedimentos de Redução de Leucócitos/utilização
Prevalência
Probabilidade
Viremia/diagnóstico
Viremia/transmissão
Inativação de Vírus
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:141001
[St] Status:MEDLINE


  5 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:24614206
[Au] Autor:Ballester LY; Cowen EW; Lee CC
[Ad] Endereço:*Laboratory of Pathology, and †Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.
[Ti] Título:Adult T-cell leukemia-lymphoma associated with follicular mucinosis.
[So] Source:Am J Dermatopathol;36(11):901-3, 2014 Nov.
[Is] ISSN:1533-0311
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Follicular mucinosis is frequently associated with follicular mycosis fungoides, but its association with adult T-cell leukemia-lymphoma (ATLL) is extremely rare. We report a case of a 50-year-old female patient with a history of ATLL, after multiple treatments, with residual/recurrent skin tumors in the forehead and legs. Biopsy of a skin tumor from the forehead revealed a perifollicular and intrafollicular atypical lymphoid infiltrate with abundant mucin deposition. Immunohistochemical stains showed that the atypical cells were positive for CD3, CD4, and CD25. Reverse transcription polymerase chain reaction performed on the tissue sections confirmed the presence of human T-cell leukemia virus in the biopsies of skin tumors. To our knowledge, this is only the third reported case of a follicular mucinosis in the setting of ATLL.
[Mh] Termos MeSH primário: Leucemia-Linfoma de Células T do Adulto/patologia
Mucinose Folicular/patologia
Neoplasias Cutâneas/patologia
[Mh] Termos MeSH secundário: Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Biomarcadores Tumorais/análise
Biópsia
Quimiorradioterapia
DNA Viral/genética
Anticorpos Antideltaretrovirus/sangue
Diagnóstico Diferencial
Feminino
Vírus 1 Linfotrópico T Humano/genética
Vírus 1 Linfotrópico T Humano/imunologia
Seres Humanos
Imuno-Histoquímica
Leucemia-Linfoma de Células T do Adulto/metabolismo
Leucemia-Linfoma de Células T do Adulto/terapia
Leucemia-Linfoma de Células T do Adulto/virologia
Meia-Idade
Mucinose Folicular/metabolismo
Valor Preditivo dos Testes
Neoplasias Cutâneas/química
Neoplasias Cutâneas/terapia
Neoplasias Cutâneas/virologia
Resultado do Tratamento
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (DNA, Viral); 0 (Deltaretrovirus Antibodies)
[Em] Mês de entrada:1506
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:140312
[St] Status:MEDLINE
[do] DOI:10.1097/DAD.0000000000000082


  6 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:22998131
[Au] Autor:Glasser L; Cyrus S; Machan JT; Mapother J
[Ad] Endereço:CBR Systems, Inc., Tucson, Arizona 85756, USA. lglasser@cordblood.com
[Ti] Título:Human T-lymphotropic virus laboratory testing of maternal blood at time of cord blood donations and clinical implications.
[So] Source:Transfusion;53(6):1302-8, 2013 Jun.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: In the United States, blood products are tested for infectious diseases including human T-lymphotropic virus (HTLV)-I/II. Positive results of maternal blood samples at the time of cord blood (CB) donation must be reported to mother and physician. Tests for HTLV have a high false-positive rate. This is problematic because there is no prenatal testing of the mother. STUDY DESIGN AND METHODS: This study involves 119,769 maternal blood samples at time of CB donation and evaluates positive results for HTLV in screening tests, supplemental immunoassays, and nucleic acid tests (NATs). Infectious disease markers (IDMs) and maternal health histories of HTLV-positive and -negative mothers were compared. RESULTS: Of 119,769 mothers donating CB, 545 tested positive with the screening test, 33 were positive with the supplemental tests, and two were positive with NAT. When indeterminate results were excluded from the supplemental test only six were positive. Eight of 34 mothers with positive or indeterminate supplemental test results had received intravenous immunoglobulin. There were no significant differences between HTLV-positive and -negative mothers with regard to the incidence of other IDMs. CONCLUSIONS: Testing maternal blood for HTLV is problematic for CB banks, obstetricians, and mothers because of the high false-positive rate. CB banks need rapid turnaround time and supplemental testing. If results on the latter are positive the obstetrician should be notified, educated, do follow-up testing, and counseling. Indeterminate results on supplemental tests are most likely false positives. We recommend that mothers with positive or indeterminate supplemental test results have follow-up NAT.
[Mh] Termos MeSH primário: Segurança do Sangue/estatística & dados numéricos
Sangue Fetal/virologia
Infecções por HTLV-I
Infecções por HTLV-II
Vírus 1 Linfotrópico T Humano/isolamento & purificação
Vírus 2 Linfotrópico T Humano/isolamento & purificação
[Mh] Termos MeSH secundário: Bancos de Sangue/estatística & dados numéricos
Anticorpos Antideltaretrovirus/sangue
Reações Falso-Positivas
Feminino
Infecções por HTLV-I/sangue
Infecções por HTLV-I/epidemiologia
Infecções por HTLV-I/transmissão
Infecções por HTLV-II/sangue
Infecções por HTLV-II/epidemiologia
Infecções por HTLV-II/transmissão
Seres Humanos
Anamnese
Gravidez
Diagnóstico Pré-Natal/estatística & dados numéricos
Prevalência
Fatores de Risco
Estudos Soroepidemiológicos
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies)
[Em] Mês de entrada:1308
[Cu] Atualização por classe:130611
[Lr] Data última revisão:
130611
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:120925
[St] Status:MEDLINE
[do] DOI:10.1111/j.1537-2995.2012.03901.x


  7 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:22927508
[Au] Autor:Bélanger SS; Fish D; Kim J; Cohen S
[Ad] Endereço:Faculté de médecine, Université de Montréal, Montréal, Québec, Canada. sophie.savary.belanger@umontreal.ca
[Ti] Título:False-positive human T-lymphotropic virus serology after intravenous immunoglobulin transfusion.
[So] Source:CMAJ;184(15):1709-12, 2012 Oct 16.
[Is] ISSN:1488-2329
[Cp] País de publicação:Canada
[La] Idioma:eng
[Mh] Termos MeSH primário: Antineoplásicos/efeitos adversos
Anticorpos Antideltaretrovirus/imunologia
Imunização Passiva
Imunoglobulinas Intravenosas/efeitos adversos
Leucemia Aguda Bifenotípica/tratamento farmacológico
Doenças da Medula Espinal/terapia
[Mh] Termos MeSH secundário: Adulto
Antineoplásicos/uso terapêutico
Reações Falso-Positivas
Soropositividade para HIV/imunologia
Seres Humanos
Imunoglobulinas Intravenosas/administração & dosagem
Leucemia Aguda Bifenotípica/diagnóstico
Masculino
Doenças da Medula Espinal/induzido quimicamente
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Deltaretrovirus Antibodies); 0 (Immunoglobulins, Intravenous)
[Em] Mês de entrada:1301
[Cu] Atualização por classe:150223
[Lr] Data última revisão:
150223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:120829
[St] Status:MEDLINE
[do] DOI:10.1503/cmaj.120019


  8 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21881482
[Au] Autor:Silva MT; Neves ES; Grinsztejn B; de Melo Espíndola O; Schor D; Araújo A
[Ad] Endereço:Laboratório de Pesquisa Clínica em Neuroinfecção, Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil. marcustulius@ipec.fiocruz.br
[Ti] Título:Neurological manifestations of coinfection with HIV and human T-lymphotropic virus type 1.
[So] Source:AIDS;26(4):521-3, 2012 Feb 20.
[Is] ISSN:1473-5571
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:HIV-individuals are at risk for human T-lymphotropic virus (HTLV) coinfection and neurological diseases. Little is known about the impact of HAART among coinfected patients. In this study, 47 out of 428 HIV individuals were coinfected with HTLV (10.9%). Coinfection was an independent variable associated with neurological outcome (odds ratio 8.73). Coinfection was associated with myelopathy [chi square (X(2)) = 93, P < 0.001], peripheral neuropathy (X(2) = 6.5, P = 0.01), and hepatitis C virus infection (X(2) = 36.5, P < 0.001). HAART did not appear to protect against neurological diseases and had no impact on HTLV proviral load.
[Mh] Termos MeSH primário: Terapia Antirretroviral de Alta Atividade
Anticorpos Antideltaretrovirus/sangue
Infecções por HIV/fisiopatologia
Infecções por HTLV-II/fisiopatologia
Vírus 1 Linfotrópico T Humano/patogenicidade
Doenças do Sistema Nervoso Periférico/virologia
Carga Viral
[Mh] Termos MeSH secundário: Contagem de Linfócito CD4
Coinfecção
Feminino
Infecções por HIV/complicações
Infecções por HTLV-II/complicações
Anticorpos Anti-Hepatite C/sangue
Seres Humanos
Masculino
Meia-Idade
Razão de Chances
Doenças do Sistema Nervoso Periférico/fisiopatologia
Doenças da Medula Espinal/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies); 0 (Hepatitis C Antibodies)
[Em] Mês de entrada:1205
[Cu] Atualização por classe:120209
[Lr] Data última revisão:
120209
[Sb] Subgrupo de revista:IM; X
[Da] Data de entrada para processamento:110902
[St] Status:MEDLINE
[do] DOI:10.1097/QAD.0b013e32834c4a3e


  9 / 350 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21476143
[Au] Autor:Baleriola C; Johal H; Robertson P; Jacka B; Whybin R; Taylor P; Rawlinson WD
[Ad] Endereço:Virology Division, SEALS, Prince of Wales Hospital, Randwick, Sydney, NSW, 2031, Australia.
[Ti] Título:Infectious disease screening of blood specimens collected post-mortem provides comparable results to pre-mortem specimens.
[So] Source:Cell Tissue Bank;13(2):251-8, 2012 Jun.
[Is] ISSN:1573-6814
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Serology assays for standard screening are optimised for use with sera collected from living adults and children. Because of potential changes in the vascular compartments after death, methods used for screening sera from cadaveric organ donors need to be validated before testing these specimens. Serum was separated from blood collected from cadaveric donors within 24 h of death and biochemical parameters measured to detect dilution of protein and haemolysis. In order to demonstrate if any inhibitors that might interfere with the assays were present, pre and post-mortem specimens were spiked with aliquots of human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis B virus (HBV), human T-cell Lymphotropic Virus (HTLV) and T. pallidum-positive sera. Comparison of serum from living subjects with serum obtained post-mortem showed that while the concentration of total protein decreased, concentrations of albumin, immunoglobulin G (IgG) and immunoglobulin M (IgM) remained unchanged. The degree of haemolysis, as measured by free haemoglobin, was within the limits accepted for the Architect analyser. Spiking of pre- and post-mortem specimens with aliquots of HIV, HCV, HBV, HTLV and T. pallidum-positive sera showed no statistical difference in the signal between pre-mortem and post-mortem results when tested on the Abbott Architect analyser. Positive results were obtained in each of a further nine subjects who had tested positive for HIV (n=1), HCV (n=8), HBV (n=1) on pre-mortem serological testing. These findings suggest that the sensitivity of the Abbott Architect serological screening tests is not significantly affected in specimens collected within 24 h of the cessation of life.
[Mh] Termos MeSH primário: Coleta de Amostras Sanguíneas/métodos
Doenças Transmissíveis/sangue
Doenças Transmissíveis/diagnóstico
Programas de Rastreamento
Mudanças Depois da Morte
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Cadáver
Anticorpos Antideltaretrovirus/sangue
Demografia
Feminino
Anticorpos Anti-HIV/sangue
Antígenos HIV/sangue
Anticorpos Anti-Hepatite B/sangue
Antígenos da Hepatite B/sangue
Anticorpos Anti-Hepatite C/sangue
Seres Humanos
Masculino
Meia-Idade
Sífilis/sangue
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies); 0 (HIV Antibodies); 0 (HIV Antigens); 0 (Hepatitis B Antibodies); 0 (Hepatitis B Antigens); 0 (Hepatitis C Antibodies)
[Em] Mês de entrada:1209
[Cu] Atualização por classe:120514
[Lr] Data última revisão:
120514
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110409
[St] Status:MEDLINE
[do] DOI:10.1007/s10561-011-9252-6


  10 / 350 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:21840754
[Au] Autor:Rafatpanah H; Hedayati-Moghaddam MR; Fathimoghadam F; Bidkhori HR; Shamsian SK; Ahmadi S; Sohgandi L; Azarpazhooh MR; Rezaee SA; Farid R; Bazarbachi A
[Ad] Endereço:Research Center for HIV/AIDS, HTLV and Viral Hepatitis, Iranian Academic Center for Education, Culture & Research (ACECR), Mashhad Branch, Mashhad, Iran.
[Ti] Título:High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey.
[So] Source:J Clin Virol;52(3):172-6, 2011 Nov.
[Is] ISSN:1873-5967
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mashhad, in the northeast of Iran has been suggested as an endemic area for human T cell lymphotropic virus type I (HTLV-I) infection since 1996. OBJECTIVES: We performed a community-based seroepidemiology study to examine the prevalence and risk factors for HTLV-I infection in the city of Mashhad. STUDY DESIGN: Between May and September 2009, overall 1678 subjects from all the 12 geographical area of Mashhad were selected randomly by multistage cluster sampling for HTLV antibody. The study population included 763 males and 915 females, with the mean age of 29.1 ± 18.5 years. 1654 serum samples were assessed for HTLV antibody using ELISA and reactive samples were confirmed by Western blot and PCR. RESULTS: The overall prevalence of HTLV-I infection in whole population was 2.12% (95% CI, 1.48-2.93) with no significant difference between males and females (p = 0.093) and the prevalence of HTLV-II seropositivity was 0.12% (95% CI, 0.02-0.44). The HTLV-I Infection was associated with age (p<0.001), marital status (p<0.001), education (p = 0.047), and history of blood transfusion (p = 0.009), surgery (p<0.001), traditional cupping (p = 0.002), and hospitalization (p = 0.004). In logistic regression analysis, age was the only variable that had a significant relation with the infection (p = 0.006, OR = 4.33). CONCLUSIONS: Our results demonstrated that Mashhad still remains an endemic area for HTLV-I infection despite routine blood screening. Thus, further strategies are needed for prevention of the virus transmission in whole population.
[Mh] Termos MeSH primário: Anticorpos Antideltaretrovirus/sangue
Infecções por HTLV-I/epidemiologia
Vírus 1 Linfotrópico T Humano/imunologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
Feminino
Vírus 1 Linfotrópico T Humano/genética
Vírus 1 Linfotrópico T Humano/patogenicidade
Seres Humanos
Lactente
Irã (Geográfico)/epidemiologia
Masculino
Meia-Idade
Prevalência
Estudos Soroepidemiológicos
Classe Social
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Deltaretrovirus Antibodies)
[Em] Mês de entrada:1204
[Cu] Atualização por classe:111018
[Lr] Data última revisão:
111018
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:110816
[St] Status:MEDLINE
[do] DOI:10.1016/j.jcv.2011.07.004



página 1 de 35 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde